Multivariate linear regression analysis.

<p>Multivariate linear regression analysis.</p

Serum Urate levels in our study cohort (MS patients, NC and HC), stratified by sex (A) and clinical phenotype(B).

<p>Figure legend. Median serum urate levels were lower in female MS (3.2 mg/dL) compared to female NC (3.5 mg/dL), and female HC (3.8 mg/dL; p = 0.004; Bonferroni’s test: female MS versus female NC p = 0.02; female MS versus female HC p = 0.01). Moreover, serum urate was lower in female with RR MS (3.1 mg/dL; compared to female NC (Bonferroni’s test: p = 0.03) and female HC (Bonferroni’s test: p = 0.04).</p

Distribution of clinical and MRI characteristics in MS patients across gender.

<p>°chi square: 8.4; p = 0.01.</p><p>°°chi square: 3; p = 0.04.</p><p>°°°chi square: 8; p = 0.002.</p

Changes of mean Cognitive Impairment Index (CII) values and of the mean FSS Score over 1 and 2 years of NTZ treatment.

*<p>Wilcoxon signed-rank test;</p>†<p>Wilcoxon signed-rank test pair-wise comparison: Year 1 vs Baseline;</p>§<p>Wilcoxon signed-rank test pair-wise comparison: Year 2 vs Baseline;</p>θ<p>Wilcoxon signed-rank test pair-wise comparison: Year 1 vs Year 2.</p

Baseline predictors of improvement of the Cognitive Impairment Index (CII) and of the Fatigue Severity Scale (FSS) at 1 year of NTZ treatment: multivariate logistic regression analysis.

<p>Abbreviations: ARR = Annualized Relapse Rate; EDSS = Expanded Disability Status Scale; BDI = Beck Depression Inventory.</p

Changes of proportion of RRMS patients with Cognitive Impairment (CI) after 1–2 year Natalizumab treatment.

<p>Changes of proportion of RRMS patients with Cognitive Impairment (CI) after 1–2 year Natalizumab treatment.</p

Plot of gender ratio by six birth decades in MS patients stratified by Latitude.

<p> <i>p-value for trend *0.0425; **&lt;0.0001.</i></p

Sex ratio, percent of relapsing onset, mean age at onset and mean time from onset to diagnosis by birth decades in female (F) and male (M) MS patients.

*<p> <i>15996 pts; p-value for trend 0.032; ^Λ14543 pts; °11998 pts; § p&lt;0.05 sex M vs. F.</i></p><p>RR = Relapsing remitting; PP = Primary progressive.</p

Sex ratio, percent of relapsing onset, mean age at onset and mean time from onset to diagnosis by birth decades and latitude in female (F) and male (M) MS patients.

<p>RR = Relapsing remitting; PP = Primary progressive.</p

Plot of gender ratio by six birth decades in MS patients from Northern and Southern Europe.

<p> <i>p-value for trend *0.0426; **&lt;0.0004.</i></p